Moreover, the S768I mutation has been associated with resistance to first-generation EGFR-TKIs, such as gefitinib and erlotinib, which are commonly used for EGFR-mutated NSCLC [25–27]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.